The Company develops and commercializes the IFP (Intelligent Fingerprinting) System, a proprietary medical device technology subject to extensive government regulation across the United States, European Union, and APAC markets, with the EU representing its largest market. The Company operates a manufacturing and design facility in Cambridge, UK, and serves hospitals, clinics, and healthcare practitioners through its core device offering, supplemented by intellectual property licensing related to biosensor technology. The Company's revenue depends on maintaining regulatory compliance, including CE marking in the EU and FDA clearance in the United States, and faces ongoing challenges from third-party supplier dependencies, rapid technological change, international IP enforcement limitations, and foreign exchange exposure.